Creabilis Pulls In Corporate VC With €15M Series B
This article was originally published in The Pink Sheet Daily
Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.
You may also be interested in...
Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.
European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.
The agency is assessing safety signals for the biologics, which are being developed for chronic pain.